News
SMARC as New Immunotherapy Marker in Cancer Patients
Immunotherapy Trial in SWI/SNF Pancreatic Cancer Patients
Immunotherapy Trial in SWI/SNF Pancreatic Cancer Patients
Genomic Profiling of UCSD patient database finds that cancer patients harboring SMARC gene alterations have improved outcomes with immunotherapy versus chemotherapy.
Immunotherapy Trial in SWI/SNF Pancreatic Cancer Patients
Immunotherapy Trial in SWI/SNF Pancreatic Cancer Patients
Immunotherapy Trial in SWI/SNF Pancreatic Cancer Patients
A second-line Pancreatic Cancer clinical trial before daraxonrasib implementing immunotherapy for SWI/SNF biomarker selected patients without combination chemotherapy.
Daraxonrasib in Pancreatic Cancer
Immunotherapy Trial in SWI/SNF Pancreatic Cancer Patients
Dr. Botta was the UCSD Principal Investigator for the pivotal Daraxonrasib trial in pancreatic cancer patients after chemotherapy. and was part of the RASolute 302 Investigators.
ctDNA in Pancreatic Cancer
A large consortium research endeavor lead by UCSD pancreatic cancer program to evaluate circulating tumor DNA as a marker of surgical and chemotherapy success and survival in pancreas patients with resectable disease.
Immunotherapy in Pancreatic Cancer
Peptide Targeting of Beta 5 Integrin
Dr. Botta and team publish early analysis of immunotherapy in pancreatic cancer patients harboring SWI/SNF Complex Mutations
Peptide Targeting of Beta 5 Integrin
Peptide Targeting of Beta 5 Integrin
A joint team between Sanford Burnham Prebys, Columbia University, and UCSD found that Fibroblasts increase B5 integrin. The iRGD peptide can deliver therapy better to this area.
Targeted Therapies in Pancreatic Cancer
Targeted Therapies in Pancreatic Cancer
Targeted Therapies in Pancreatic Cancer
Dr. Botta discusses targeted therapies in advanced pancreatic cancer in the publication 'Targeted Oncology' - 11/26/2020
Padres Pedal The Cause Grant Award
Targeted Therapies in Pancreatic Cancer
Targeted Therapies in Pancreatic Cancer
The Botta laboratory in conjunction with the lab of Ronald Evans at Salk Institute receive a grant to study immune targeting in pancreatic cancer.
Circulating Tumor DNA in Colon Cancer
Targeted Therapies in Pancreatic Cancer
Circulating Tumor DNA in Colon Cancer
Dr. Botta discusses ctDNA and molecular residual disease at the ASCO Denver meeting.
ctDNA Surveillance During COVID
Gastric Cancer Therapy Roundtable
Circulating Tumor DNA in Colon Cancer
Multiple part series on ctDNA and its use in detecting residual disease in Gastrointestinal Cancers during COVID-19 by Dr. Botta
UCSD Industry Symposium
Gastric Cancer Therapy Roundtable
Gastric Cancer Therapy Roundtable
Discussion of the targeted pancreatic cancer therapies being developed at the Botta Lab - 2/20/2020
Gastric Cancer Therapy Roundtable
Gastric Cancer Therapy Roundtable
Gastric Cancer Therapy Roundtable
As part of the SSO, Dr. Botta joins Drs. Kelly and Simpson of UCSD to discuss Gastric cancer therapies with internationally leading experts
Publications
1.) Botta, G.P., de Mendoza, T.H., Sugahara, K., Ruoslahti, E. “Oncogenic Kras Regulates Glucose Dependent iRGD Tumor-Targeting in Pancreatic Cancer.” 2020.
2.) Bhangoo, M., Cheng, B., Botta, G.P., Kosty, M. “Reversible Intrahepatic Cholestasis in Metastatic Prostate Cancer: An Uncommon Paraneoplastic Syndrome.” Molecular and Clinical Oncology. 2018. DOI: 10.3892/mco.2018.1564.
3.) Botta, L.M., Botta, G.P. “Hyperbaric Oxygen Therapy during BK Virus Hemorrhagic Cystitis in Post-Transplant Acute Lymphoblastic Leukemia.” Clinical Journal of Oncology Nursing. 2018.
4.) Botta, G.P., Granowicz, E., Costantini, C. “Advances on Immunotherapy in Genitourinary and Renal Cell Carcinoma”. Translational Cancer Research. 2017. DOI: 10.21037/tcr.2017.02.09
5.) Sarcon, A., Botta, G.P., Rogowitz, E., Stubblefield, S., Rubenson, D., Patel, N., Van Niekerk, C., Triffon, D., Sigal, D. “Anaplastic Metastasis of Left-Sided Cardiac Carcinoid with Rapid Tricuspid Valve Involvement after Valve Replacement.” Journal of Clin. Case. 2016. DOI: 10.4172/2165-7920.1000907
6.) Sarcon, A., Botta, G.P., Patel, N., Saven, A. “Spontaneous Iliopsoas Muscle Hemorrhage Secondary to Ibrutinib (Imbruvica; Pharmacyclics): Brief Report.” Journal of Investig. Med. 2016. DOI: 10.1177/2324709616648457
7.) Botta, G.P., Reichert, M., Reginato, M.J., Heeg, S., Rustgi, A.K., Lelkes, P.I. “Tailored Targeting of Inflamed, Regenerative, and Mutated K-RasG12D Upregulated cDNA Microarray Gene Signatures in Pancreatic Ductal Cells”. European Journal of Human Genetics. 2014. Volume 22(1)
8.) Reichert, M., Takano, S., Heeg, S., Bakir, B., Botta, G.P., Rustgi, A.K. “Isolating Murine Pancreatic Ductal Cells using Magnetic Beads in Development, Regeneration and Cancer”. Nature Protocols. 2013. PMID: 23787893
9.) Botta, G.P., Reichert M., Reginato, M., Heeg, S., Rustgi, A.K., Lelkes, P.I. “ERK2-Regulated TIMP-1 Induces
Hyperproliferation of K-RasG12D Transformed Pancreatic Ductal Cells”. Neoplasia. 2013. PMCID: PMC3612909
10.) Frohbergh, M., Katsman, A., Botta, G.P., Lazarovici, P., Lelkes, P.I. “Electrospun Mineralized Chitosan Nanofibers Crosslinked with Genipin for Bone Tissue Engineering”. Biomaterials. 2012. DOI:10.1016/j.biomaterials.2012.09.009
11.) Botta, G.P. “K-RasG12D Activation of ERK2 Regulates Pancreatic Cancer Oncogenesis in 3-D”. ProQuest Dissertations & Theses. 2012. ISBN: 9781267441768
12.) Botta, G.P., Reginato, M.R., Reichert, M., Rustgi, A.K., Lelkes, P.I. “Constitutive K-RasG12D Activation of ERK2 Specifically Regulates 3-D Invasion of Human Pancreatic Cancer Cells via MMP-1”. Molecular Cancer Research. 2012. Highlight Article. DOI: 10.1158/1541-7786.MCR-11-0399
13.) Drowley, L., Okada, M., Payne, T., Botta, G.P., Oshima, H., Tobita, K., Keller, B., Huard, J. “Lack of Sex Differences in Muscle Stem Cell Transplantation for Cardiac Repair.” Cell Transplantation. 2009. DOI:10.3727/096368909X471305
14.) Botta, G.P., Manly, P., Miller, S., Lelkes, P.I. "Real-time Assessment of Three-Dimensional Cell Aggregation in Rotating Wall Vessel Bioreactors in vitro." Nature Protocols. 2007. DOI:10.1038/nprot.2006.311
Publications in Preparation (Abstracts available upon request)
1.) Botta, G.P., de Mendoza, T.H., Sugahara, K., Teyton, L., Ruoslahti, E. “Reversing Pancreatic Cancer Myeloid and Treg Immunosuppression with Tumor-Penetrating Peptides”.
2.) Botta, G.P., Huynh, T., Schaffer, R., Lin, R., Sigal, D. “Neoadjuvant Chemoradiotherapy in Borderline Resectable Pancreatic Adenocarcinoma Patients”.
3.) de Mendoza, T.H., Botta, G.P., Ruoslahti, E., Sugahara, K. “iRGD Stromal Targeting and Metastasis are Regulated by Integrin b5 in Pancreatic Cancer.”
4.) Botta, G.P., Reichert, M., Yang, W., Takano, S., Heeg, S., Rustgi, A.K. “Prrx1 Transcription Factor Variants Alter iPSC Induction Efficiency and Terminal Differentiation.”
Invited Book Chapters
1.) Botta, G.P., Blonski, W., Lichtenstein, G.R. (2014). Cyclosporine for Ulcerative Colitis, Medical Therapy of Ulcerative Colitis. G.R. Lichtenstein (ed.), Springer Science + Business Media, New York. DOI: 10.1007/978-1-4939-1677-1_13
